Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA
vaccines updated for fall 2023 in adults aged ≥18 years over a 1-year analytic time horizon (…

Objective The objective of this study was to evaluate the cost effectiveness of no prophylaxis,
primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-…

Full article: Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile
neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-…

Objective Emerging SARS-COV-2 variants are spurring the development of adapted vaccines
as public health authorities plan for fall vaccinations. This study estimated the number of …

OBJECTIVES: This analysis estimated the cost per response and the incremental cost per
additional responder of romplostim, eltrombopag, and the “watch-and-rescue”(monitoring until …

This analysis estimates the economic and clinical impact of a Moderna updated COVID-19
mRNA Fall 2023 vaccine for adults ≥18 years in Japan. A previously developed Susceptible-…

Objectives To assess the potential clinical impact and cost-effectiveness of coronavirus
disease 2019 (COVID-19) mRNA vaccines updated for Autumn 2023 in adults aged ≥60 years …

Objective Evaluate the cost-effectiveness of primary prophylaxis (PP) or secondary prophylaxis
(SP) with pegfilgrastim, filgrastim (6-day and 11-day), or no prophylaxis to reduce the risk …

Introduction: We reviewed the evolution of the methods used in cost-effectiveness analyses
of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention …

Background: Immunocompromised (IC) individuals are at increased risk of COVID-19
infection-related severe outcomes. Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines are …